看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | -8.6x - -9.5x | -9.1x |
| Selected Fwd EBIT Multiple | -4.7x - -5.2x | -4.9x |
| Fair Value | $0.51 - $0.54 | $0.52 |
| Upside | 72.5% - 82.9% | 77.7% |
| Benchmarks | Ticker | Full Ticker |
| Guanhao Biotech Co.,Ltd. | 300238 | SZSE:300238 |
| Keymed Biosciences Inc. | 2162 | SEHK:2162 |
| Xiamen Amoytop Biotech Co., Ltd. | 688278 | SHSE:688278 |
| Jiangsu Aidea Pharmaceutical Co., Ltd. | 688488 | SHSE:688488 |
| Abbisko Cayman Limited | 2256 | SEHK:2256 |
| Jacobio Pharmaceuticals Group Co., Ltd. | JBPH.F | OTCPK:JBPH.F |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| 300238 | 2162 | 688278 | 688488 | 2256 | JBPH.F | ||
| SZSE:300238 | SEHK:2162 | SHSE:688278 | SHSE:688488 | SEHK:2256 | OTCPK:JBPH.F | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | 3.1% | NM- | 54.8% | NM- | NM- | NM- | |
| 3Y CAGR | -1.5% | NM- | 63.4% | NM- | NM- | NM- | |
| Latest Twelve Months | 117.6% | -36.9% | 46.6% | -48.6% | 95.8% | 50.7% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 0.7% | -317.1% | 23.8% | -25.8% | -1922.1% | -382.6% | |
| Prior Fiscal Year | -14.6% | -129.2% | 31.4% | -24.8% | -2681.4% | -648.5% | |
| Latest Fiscal Year | 9.8% | -146.2% | 34.3% | -36.2% | -4.3% | -130.5% | |
| Latest Twelve Months | 2.5% | -146.2% | 34.3% | -36.2% | -4.3% | -130.5% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 8.69x | 23.09x | 11.03x | 12.05x | 4.42x | 8.91x | |
| EV / LTM EBITDA | 112.7x | -17.2x | 30.0x | -45.8x | -145.9x | -7.2x | |
| EV / LTM EBIT | 345.2x | -15.8x | 32.1x | -33.3x | -103.2x | -6.8x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -103.2x | -15.8x | 345.2x | ||||
| Historical EV / LTM EBIT | -1420.5x | -6.8x | -3.3x | ||||
| Selected EV / LTM EBIT | -8.6x | -9.1x | -9.5x | ||||
| (x) LTM EBIT | (203) | (203) | (203) | ||||
| (=) Implied Enterprise Value | 1,748 | 1,840 | 1,932 | ||||
| (-) Non-shareholder Claims * | 1,041 | 1,041 | 1,041 | ||||
| (=) Equity Value | 2,788 | 2,880 | 2,972 | ||||
| (/) Shares Outstanding | 653.6 | 653.6 | 653.6 | ||||
| Implied Value Range | 4.27 | 4.41 | 4.55 | ||||
| FX Rate: CNY/USD | 7.3 | 7.3 | 7.3 | Market Price | |||
| Implied Value Range (Trading Cur) | 0.58 | 0.60 | 0.62 | 0.30 | |||
| Upside / (Downside) | 97.7% | 104.2% | 110.7% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | 300238 | 2162 | 688278 | 688488 | 2256 | JBPH.F | |
| Enterprise Value | 3,233 | 10,161 | 31,033 | 4,934 | 2,262 | 370 | |
| (+) Cash & Short Term Investments | 107 | 2,156 | 662 | 472 | 2,008 | 1,175 | |
| (+) Investments & Other | 34 | 210 | 57 | 0 | 0 | 18 | |
| (-) Debt | (98) | (753) | (9) | (483) | (24) | (152) | |
| (-) Other Liabilities | 75 | (1) | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 3,352 | 11,773 | 31,743 | 4,923 | 4,245 | 1,410 | |
| (/) Shares Outstanding | 265.2 | 275.6 | 406.8 | 420.8 | 625.3 | 653.6 | |
| Implied Stock Price | 12.64 | 42.72 | 78.03 | 11.70 | 6.79 | 2.16 | |
| FX Conversion Rate to Trading Currency | 1.00 | 0.94 | 1.00 | 1.00 | 0.94 | 7.32 | |
| Implied Stock Price (Trading Cur) | 12.64 | 45.30 | 78.03 | 11.70 | 7.20 | 0.30 | |
| Trading Currency | CNY | HKD | CNY | CNY | HKD | USD | |
| FX Rate to Reporting Currency | 1.00 | 0.94 | 1.00 | 1.00 | 0.94 | 7.32 | |